Literature DB >> 20884827

Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

S Vincent Rajkumar1, Robert A Kyle, Francis K Buadi.   

Abstract

Mesh：

Year:  2010        PMID： 20884827      PMCID： PMC2947967          DOI： 10.4065/mcp.2010.0520

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  34 in total

1.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

Review 2.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

3.  Bone disease in multiple myeloma.

Authors:  Matthew T Drake
Journal:  Oncology (Williston Park)       Date:  2009-12       Impact factor: 2.990

4.  Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.

Authors:  Celine M Vachon; Robert A Kyle; Terry M Therneau; Barbara J Foreman; Dirk R Larson; Colin L Colby; Tara K Phelps; Angela Dispenzieri; Shaji K Kumar; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

5.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

6.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

7.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

8.  Prevention of progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

Review 9.  Pathogenesis of myeloma bone disease.

Authors:  G D Roodman
Journal:  Leukemia       Date:  2008-11-27       Impact factor: 11.528

10.  Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan.

Authors:  Masako Iwanaga; Masuko Tagawa; Kunihiro Tsukasaki; Shimera Kamihira; Masao Tomonaga
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616
View more
  28 in total

1.  Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder.

Authors:  E A Engels; J Preiksaitis; A Zingone; O Landgren
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

2.  [Monoclonal gammopathy of undetermined significance and monoclonal B-lymphocytosis].

Authors:  K Hübel; M Hallek
Journal:  Internist (Berl)       Date:  2013-06       Impact factor: 0.743

Review 3.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.

Authors:  Neha Korde; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Blood       Date:  2011-03-25       Impact factor: 22.113

4.  Monoclonal gammopathy of undetermined significance associated with blue finger syndrome.

Authors:  Alaa M Ali; Aibek E Mirrakhimov
Journal:  BMJ Case Rep       Date:  2013-01-03

Review 5.  Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.

Authors:  Srinath Sundararajan; Abhijeet Kumar; Neha Korde; Amit Agarwal
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

6.  IgM Myeloma or Waldenstrom's Macroglobulinemia Is the Big Question?

Authors:  Vijaya Raj Bhatt; Srujitha Murukutla; Muniba Naqi; Shradha Pant; Shiksha Kedia; Terenig Terjanian
Journal:  Maedica (Buchar)       Date:  2014-03

7.  When an Analytical Interference Is a Useful Diagnostic Tool: Finding Monoclonal Gammopathies in Routine Analysis.

Authors:  Carmen Quiñones-Torrelo; María Pilar Villanueva-Gil; Ana Rodríguez-Muñoz; Lidia Abellán-Tejada; Manuel Aparici-Ibáñez; Arturo Carratalá-Calvo
Journal:  J Clin Lab Anal       Date:  2014-12-26       Impact factor: 2.352

Review 8.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

9.  Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.

Authors:  Brenda M Birmann; Marian L Neuhouser; Bernard Rosner; Demetrius Albanes; Julie E Buring; Graham G Giles; Qing Lan; I-Min Lee; Mark P Purdue; Nathaniel Rothman; Gianluca Severi; Jian-Min Yuan; Kenneth C Anderson; Michael Pollak; Nader Rifai; Patricia Hartge; Ola Landgren; Lawrence Lessin; Jarmo Virtamo; Robert B Wallace; JoAnn E Manson; Graham A Colditz
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

10.  [Multiple myeloma].

Authors:  K M Kortüm; M Engelhardt; L Rasche; S Knop; H Einsele
Journal:  Internist (Berl)       Date:  2013-08       Impact factor: 0.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.